This page shows the latest breast cancer drug news and features for those working in and with pharma, biotech and healthcare.
An estimated 2.3 million patients were diagnosed with breast cancer in 2020. ... In the EU, this indication also includes patients with locally advanced breast cancer.
European patients with metastatic triple-negative breast cancer can now receive the antibody-drug conjugate as second-line monotherapy. ... Effective treatment options are extremely limited in TNBC compared with other breast cancer types and the chance
year. As part of the programme, Pfizer has provided an independent medical research grant to Breast Cancer Now. ... We hope our trial will show that, when combined with immunotherapy, aspirin can enhance its effects and may ultimately provide a safe new
NICE declares Lilly’s breast cancer drug to be cost-effective, allowing routine use on the NHS. ... The drug is already approval on the NHS for previously untreated, hormone-receptor positive, HER2-negative, locally advanced or metastatic breast cancer.
Lynparza became the first drug in the PARP inhibitor class to be approved in BRCA-positive breast cancer previously treated with chemotherapy in 2018. ... With AZ/Merck &Co already working with regulators to bring Lynparza to the market, a potential
in a group of heavily pre-treated triple negative breast cancer (TNBC) patients. ... In December 2019, Enhertu won approval from the US Food and Drug Administration for metastatic HER2-positive breast cancer patients who have previously been treated
More from news
Approximately 1 fully matching, plus 221 partially matching documents found.
Trastuzumab successfully reduced the aggressiveness of breast cancer cells, helping to improve the lives of those suffering with the condition. ... This treatment quickly became the ‘gold standard’ for women with metastatic breast cancer.
and Braftovi) that Pfizer thinks could become a top industry franchise in colorectal cancer when combined with antibody drug cetuximab. ... to 2025 built on the Prevnar franchise, rare disease therapy Vyndaqel (tafamidis), breast cancer therapy Ibrance
keep it inhibited – and which also run the risk of cancer cells acquiring resistance by developing receptor mutations. ... this way. AstraZeneca’s injectable drug Faslodex (fulvestrant) for breast cancer has been approved since 2002, and acts by
The HER2-targeting antibody-drug conjugate (ADC) combines the HER2-targeting of Roche’s blockbuster breast cancer therapy Herceptin (trastuzumab) with a cell-killing chemotherapy component designed to improve its ability ... Moreover, they think there
At the Leveraging EHR for Clinical Research Now! event, leaders from academia, companies including Amgen and AstraZeneca and the US Food and Drug Administration sought to identify the factors that are ... Pfizer, for example, won an expanded FDA label
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
investigational medicines, such as breast cancer drug T-DM1.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
After graduation, Danni interned at Novartis Pharmaceuticals on the marketing and commercial team, working on the launch of their metastatic breast cancer drug.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...